Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Procedures, Operative | 2 | 2013 | 79 | 0.750 |
Why?
|
| Fibroma | 2 | 2010 | 11 | 0.640 |
Why?
|
| Quality Indicators, Health Care | 2 | 2013 | 62 | 0.490 |
Why?
|
| Biopsy, Fine-Needle | 11 | 2016 | 62 | 0.460 |
Why?
|
| Choledocholithiasis | 1 | 2015 | 4 | 0.440 |
Why?
|
| Gallstones | 1 | 2015 | 11 | 0.440 |
Why?
|
| Appendix | 1 | 2014 | 6 | 0.420 |
Why?
|
| Peritoneal Neoplasms | 2 | 2014 | 256 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 28 | 0.410 |
Why?
|
| Abdomen | 1 | 2013 | 44 | 0.400 |
Why?
|
| Laparoscopy | 3 | 2014 | 184 | 0.390 |
Why?
|
| Retrospective Studies | 15 | 2015 | 3609 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 148 | 0.370 |
Why?
|
| Breast Neoplasms | 5 | 2008 | 763 | 0.370 |
Why?
|
| Sarcoma | 2 | 2010 | 82 | 0.370 |
Why?
|
| Female | 26 | 2016 | 19935 | 0.350 |
Why?
|
| Bone Neoplasms | 2 | 2009 | 104 | 0.330 |
Why?
|
| Epithelioid Cells | 1 | 2010 | 2 | 0.330 |
Why?
|
| Calcinosis | 2 | 2008 | 142 | 0.330 |
Why?
|
| Humans | 34 | 2016 | 32262 | 0.320 |
Why?
|
| Aged | 18 | 2015 | 10249 | 0.310 |
Why?
|
| Postoperative Complications | 2 | 2013 | 818 | 0.300 |
Why?
|
| Adenoma | 1 | 2009 | 35 | 0.290 |
Why?
|
| Male | 20 | 2015 | 19429 | 0.290 |
Why?
|
| Hoarseness | 1 | 2008 | 3 | 0.290 |
Why?
|
| Vocal Cords | 1 | 2008 | 10 | 0.280 |
Why?
|
| Laryngeal Diseases | 1 | 2008 | 10 | 0.280 |
Why?
|
| Middle Aged | 19 | 2016 | 11837 | 0.270 |
Why?
|
| Adult | 16 | 2015 | 9252 | 0.260 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 200 | 0.250 |
Why?
|
| Sarcoma, Synovial | 1 | 2006 | 6 | 0.250 |
Why?
|
| Ganglion Cysts | 1 | 2006 | 8 | 0.250 |
Why?
|
| Living Donors | 1 | 2007 | 61 | 0.250 |
Why?
|
| Program Evaluation | 1 | 2007 | 171 | 0.240 |
Why?
|
| Nephrectomy | 1 | 2007 | 123 | 0.240 |
Why?
|
| Diagnosis, Differential | 9 | 2016 | 500 | 0.230 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2015 | 23 | 0.220 |
Why?
|
| Splenic Neoplasms | 1 | 2004 | 2 | 0.210 |
Why?
|
| Aspergillosis | 1 | 2004 | 9 | 0.210 |
Why?
|
| Esophageal Diseases | 1 | 2004 | 8 | 0.210 |
Why?
|
| Carcinoma | 3 | 2016 | 92 | 0.210 |
Why?
|
| Esophagus | 1 | 2004 | 29 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2015 | 3893 | 0.210 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2003 | 3 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 21 | 0.200 |
Why?
|
| Cadherins | 1 | 2004 | 28 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 131 | 0.200 |
Why?
|
| Kidney Transplantation | 1 | 2007 | 490 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2013 | 553 | 0.190 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2002 | 2 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 211 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2016 | 36 | 0.170 |
Why?
|
| Neutrophils | 1 | 2002 | 120 | 0.170 |
Why?
|
| Quebec | 2 | 2013 | 3 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3408 | 0.160 |
Why?
|
| Adolescent | 9 | 2012 | 3509 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2013 | 1839 | 0.150 |
Why?
|
| Child | 7 | 2007 | 2430 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 164 | 0.130 |
Why?
|
| Acrospiroma | 1 | 2016 | 4 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 31 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 442 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2015 | 476 | 0.110 |
Why?
|
| Cholecystostomy | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cholangitis | 1 | 2015 | 4 | 0.110 |
Why?
|
| Cholecystitis | 1 | 2015 | 4 | 0.110 |
Why?
|
| Pancreatitis | 1 | 2015 | 20 | 0.110 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 29 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 50 | 0.110 |
Why?
|
| Parotid Gland | 2 | 2012 | 8 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 19 | 0.110 |
Why?
|
| Biopsy, Needle | 3 | 2003 | 93 | 0.100 |
Why?
|
| Recurrence | 1 | 2015 | 286 | 0.100 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2013 | 13 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 534 | 0.100 |
Why?
|
| Parotitis | 1 | 2012 | 3 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 772 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 23 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2012 | 33 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2010 | 65 | 0.090 |
Why?
|
| Appendiceal Neoplasms | 1 | 2013 | 99 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 298 | 0.090 |
Why?
|
| Survival Rate | 1 | 2014 | 892 | 0.090 |
Why?
|
| Splenic Diseases | 1 | 2011 | 4 | 0.090 |
Why?
|
| Melanoma | 2 | 2004 | 166 | 0.090 |
Why?
|
| Splenectomy | 1 | 2011 | 22 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 20 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 236 | 0.080 |
Why?
|
| Hemangioma | 1 | 2011 | 22 | 0.080 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 19 | 0.080 |
Why?
|
| Azure Stains | 1 | 2010 | 1 | 0.080 |
Why?
|
| Mitral Valve | 1 | 2011 | 33 | 0.080 |
Why?
|
| Methylene Blue | 1 | 2010 | 3 | 0.080 |
Why?
|
| Xanthenes | 1 | 2010 | 4 | 0.080 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2010 | 2 | 0.080 |
Why?
|
| Parotid Neoplasms | 1 | 2010 | 5 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2006 | 544 | 0.080 |
Why?
|
| Prognosis | 1 | 2014 | 1529 | 0.080 |
Why?
|
| WT1 Proteins | 1 | 2009 | 4 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 15 | 0.070 |
Why?
|
| Radiography | 2 | 2007 | 358 | 0.070 |
Why?
|
| Laryngoscopy | 1 | 2008 | 37 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2011 | 329 | 0.070 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2008 | 1 | 0.070 |
Why?
|
| Dermatomyositis | 1 | 2008 | 18 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2009 | 113 | 0.070 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2007 | 2 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2008 | 50 | 0.070 |
Why?
|
| Methotrexate | 1 | 2008 | 70 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 113 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2238 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 43 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 248 | 0.060 |
Why?
|
| Foot | 1 | 2006 | 40 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2008 | 135 | 0.060 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2006 | 1 | 0.060 |
Why?
|
| Lung | 1 | 2008 | 263 | 0.060 |
Why?
|
| Mammography | 2 | 2003 | 41 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2007 | 236 | 0.060 |
Why?
|
| Graft Survival | 1 | 2007 | 293 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 2005 | 7 | 0.060 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2004 | 3 | 0.050 |
Why?
|
| Mesoderm | 1 | 2004 | 12 | 0.050 |
Why?
|
| Hamartoma | 1 | 2004 | 9 | 0.050 |
Why?
|
| Cartilage | 1 | 2004 | 33 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2015 | 309 | 0.050 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2004 | 12 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Nevus | 1 | 2004 | 17 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 16 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 33 | 0.050 |
Why?
|
| Keratins | 1 | 2004 | 39 | 0.050 |
Why?
|
| Incidence | 1 | 2007 | 1241 | 0.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 19 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 94 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2003 | 34 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2004 | 113 | 0.050 |
Why?
|
| Breast | 1 | 2003 | 63 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 27 | 0.050 |
Why?
|
| Lymphocytes, Null | 1 | 2002 | 1 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2002 | 16 | 0.050 |
Why?
|
| Vincristine | 1 | 2002 | 24 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 37 | 0.050 |
Why?
|
| Etoposide | 1 | 2002 | 38 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 32 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 28 | 0.040 |
Why?
|
| Prednisone | 1 | 2002 | 69 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2002 | 83 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2002 | 75 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 140 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 220 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 1211 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 373 | 0.040 |
Why?
|
| Ontario | 1 | 2015 | 5 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 58 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 63 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2007 | 1233 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 21 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 49 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 551 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 72 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 287 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 393 | 0.020 |
Why?
|
| Dry Eye Syndromes | 1 | 2008 | 4 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 2008 | 8 | 0.020 |
Why?
|
| Raynaud Disease | 1 | 2008 | 13 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2008 | 12 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2008 | 15 | 0.020 |
Why?
|
| Azathioprine | 1 | 2008 | 27 | 0.020 |
Why?
|
| Vasculitis | 1 | 2008 | 26 | 0.020 |
Why?
|
| Dyspnea | 1 | 2008 | 32 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2008 | 28 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 2008 | 37 | 0.020 |
Why?
|
| Arthritis | 1 | 2008 | 30 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 56 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2006 | 8 | 0.020 |
Why?
|
| Hepatoblastoma | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2006 | 20 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2006 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 24 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 20 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 756 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2005 | 45 | 0.010 |
Why?
|
| Medical Records | 1 | 2005 | 75 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2004 | 20 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 47 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 39 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 37 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 71 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 168 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 904 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1010 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 339 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 146 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 221 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 346 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 232 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 880 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 2315 | 0.010 |
Why?
|